Reference List. Neither Party shall be entitled to put the other Party’s name on a reference list without the other Party’s prior written approval.
Reference List. A vivid description of works similar to the one in tender and carried out by the tenderer shall be included. It shall especially mention the following data: names and surnames of the contact persons, full addresses, telephone and fax numbers and e-mails. The tenderer should include similar information regarding its sub-contractors.
Reference List. Articles:
Reference List. In Chapter 4 and 5, genome wide gene expression experiments are presented, analyzing the effect of mitochondria with an A3243G mutation or total DNA depletion (ρ0 cells) on nuclear gene expression, with the aim to uncover mutation-specific nuclear transcriptional responses. In Chapter 5 additional experiments are described to dissect the signaling of mitochondrial dysfunction to the cytosolic protein synthesis machinery. Chapter 6 discusses experimental results.
Reference List. Baxter shall be entitled to put Client’s name on a reference list if Client does not explicitly object to such procedure.
Reference List. Hogewoning A.A., et all. Skindiseases among schoolchildren in Ghana, Gabon and Rwanda. August 2012 ; accepted for publication in the International Journal of Dermatology
Reference List. Baxter shall be entitled to put Dynavax’s name on a reference list if Dynavax does not explicitly object to such procedure.
Reference List. OMNINET and the Distributor may include Your name and further information being publicly available in a reference list, which may also be published on the Internet. Any other advertising references must be discussed with You in advance.
Reference List. A list of references from recent work performed by the Contractor and all sub-contractors’ that will perform work for Xxxx County must be submitted with the Contractor’s bid package. Each prospective Contractor shall provide a minimum of five references of recent work completed on a FBR’s. The reference list must include the following information for each reference:
A. Name of the site where FBR construction or repairs were performed
B. Location of the FBR
C. Incinerator size and type
D. Type of incinerator application E. Actual date of start-up after the referenced Work F. Name of construction xxxxxxx
Reference List. Atea Pharmaceuticals, Inc. AT-752. Investigator’s brochure, edition No. 2 Boston (MA). 2021. Center for Disease Control and Prevention (CDC). Dengue. July 2020 [cited 03 Dec 2020] [13 screens]. Available from: xxxxx://xxx.xxx.xxx/dengue/index.html. Dengvaxia Package Insert. Jun 2019 [cited 03 Dec 2020] [16 pages] Available from: xxxxx://xxx.xxx.xxx/media/124379/download. Department of Health and Human Services (DHHS), Food and Drug Administration (DHHS), Center for Drug Evaluation and Research (US). Guidance for industry: Food-effect bioavailability and fed bioequivalence studies. December 2002 [03 Dec 2020] [12 screens]. Available from: xxxx://xxx.xxx.xxx/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance s/UCM070241.pdf Department of Health and Human Services (DHHS), Food and Drug Administration, Center for Drug Evaluation and Research (US). Guidance for Industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. July 2005 [cited 03 Dec 2020] [30 screens]. Available from: xxxx://xxx.xxx.xxx/downloads/Drugs/Guidances/UCM078932.pdf Department of Health and Human Services (DHHS), National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 2.1. July 2017 [cited 2020 Dec 10] [35 screens]. Available from: xxxxx://xxx.xxxxx.xxx.xxx/sites/default/files/daidsgradingcorrectedv21.pdf Xxxxx AS, Xxxxxx X, Xxxxxx T, et al; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Xxx Intern Med. 2006;145(4):247-54. Xxx JG, Xxxx C, Xxxxxx L, et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of- concept trial. Lancet Infect Dis. 2014;14:706-715. Xxx JG, Xxxxxxxx R, Xxxxxxxxx XX, et al. Dengue Antiviral Development: A Continuing Journey. Adv Exp Med Biol. 2018;1062:319-32. CCI Xxxxxx NM, Xxxx CN, Xxxxx XX, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013;207(9):1442-50. Xxxxxx A, Xxxxx LE, Xxxxx XX, et al. Travel-associated and locally acquired dengue cases-United States, 2010–2017. MMWR Morb Mortal Wkly Rep. 2020;69:149-154.